1. Home /
    2. Altai Protocol Library /
  2. New Drug: Loncastuximab tesirine for relapsed/refractory DLBCL

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Drug: Loncastuximab tesirine for relapsed/refractory DLBCL

New Drug: Loncastuximab tesirine for relapsed/refractory DLBCL
Study:
  • Open-label phase II study (LOTIS-2)
  • Relapsed/refractory diffuse large B-cell lymphoma with >=2 prior therapies
  • Loncastuximab q3wk (N=145)
Efficacy:
  • CRR: 24.1%, ORR: 48.3%
  • Median DoR: 10.3 mos
  • ORR among double/triple-hit: 33%; refractory to most recent therapy: 37%; who had prior SCT: 58%, who received prior CAR-T therapy: 46%
Safety:
  • Grade >=3 AEs: neutropenia (30%), thrombocytopenia (17%), anemia (10%), edema (3%), fatigue (1%)

Blood. Nov 2020. 136 (Supplement 1):35-37

Caimi PF, et al. Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

https://doi.org/10.1182/blood-2020-137524

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More